Methods of treating essential tremor
A compound of formula (I) or its salt reduces tremor severity and functional disability in essential tremor by daily administration, addressing the inadequacies of existing treatments.
Patent Information
- Application Number
- HK62026125171
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-10-02
- Filing Date
- 2026-06-23
- Publication Date
- 2026-07-31
AI Technical Summary
Current treatments for essential tremor are inadequate in effectively reducing tremor severity and associated functional disability.
Administration of a compound of formula (I) or its pharmaceutically acceptable salt at a daily dose of 60-100 mg significantly reduces the TETRAS performance score in subjects with essential tremor.
The compound effectively decreases tremor severity and functional disability in essential tremor patients.
Smart Images
Figure 00000074_0000 
Figure 00000075_0000 
Figure 00000076_0000
Abstract
Description
Abstract This disclosure relates to a method for treating essential tremor, the method comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered to the subject once daily at a dose of about 60 mg to about 100 mg; such that, after administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof, the subject's TETRAS performance score is reduced compared to the subject's TETRAS performance score before administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof.
Claims
CLAIMS1. A method of treating essential tremor, said method comprising administering to a subject in need thereof compound of formula (I):or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject once daily at a dose of about 60 mg to about 100 mg; such that The Essential Tremor Rating Assessment Scale (TETRAS) performance score of said subject is decreased following administration of the compound of formula (I), or a pharmaceutically acceptable salt thereof, as compared to the TETRAS performance score of said subject prior to the administration of the compound of formula (I), or a pharmaceutically acceptable salt thereof.
2. The method of claim 1, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to said subject at a dose of about 60 mg.
3. The method of claim 1, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is administered to said subject at a dose of about 100 mg.
4. The method of any one of claims 1-3, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is administered to said subject following an initial titration period.
5. The method of claim 4, wherein the compound of formula (I), or a pharmaceutically acceptalbe salt thereof, is administered to said subject at a dose of about 60 mg following an initial titration period; wherein said initial titration period comprises administering to the subject the compound of formula (I), or a pharmaceutically acceptable salt thereof, once daily at a dose of about 5 mg during a first time period; followed by a dose of about 10 mg during a second time period;followed by a dose of about 20 mg during a third time period; followed by a dose of about 40 mg during a fourth time period.
6. The method of claim 5, wherein the first time period, the second time period, the third time period and the fourth time period are each 7 days long.
7. The method of claim 4, wherein the compound of formula (I), or a pharmaceutically acceptalbe salt thereof, is administered to said subject at a dose of about 100 mg following an initial titration period; wherein said initial titration period comprises administering to the subject the compound of formula (I), or a pharmaceutically acceptable salt thereof, once daily at a dose of about 5 mg during a first time period; followed by a dose of about 10 mg during a second time period; followed by a dose of about 20 mg during a third time period; followed by a dose of about 40 mg during a fourth time period; followed by a dose of about 60 mg during a fifth time period, followed by a dose of about 80 mg during a sixth time period.
8. The method of claim 7, wherein the first time period, the second time period, the third time period, the fourth time period, the fifth time period and the sixth time period are each 7 days long.
9. The method of any one of claims 1-8, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject for at least 8 weeks.
10. The method of any one of claims 1-8, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject for at least 12 weeks.
11. The method of any one of claims 1-8, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject for at least 14 weeks.
12. The method of any one of claims 1-8, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject for at least 52 weeks.
13. The method of any one of claims 1-12, wherein the TETRAS performance score comprises ADL subscore, and wherein the ADL subscore is decreased by at least about 0.5 points, at least about 1 point, at least about 1.5 points, at least about 2 points, at least about 2.5 points, at least about 3 points, at least about 3.5 points, at least about 4 points, at least about 4.5points, at least about 5 points, at least about 5.5 points, at least about 6 points, at least about 6.5 points, at least about 7 points, at least about 7.5 points, at least about 8 points, at least about 8.5 points, at least about 9 points, at least about 9.5 points or at least about 10 points following administration of the compound of formula (I), as compared to the ADL subscore of said subject prior to the administration of the compound of formula (I).
14. The method of claim 13, wherein the ADL subscore is decreased by at least about 2 points following at least 8 weeks of administration of the compound of formula (I), or a pharmaceutically acceptable salt thereof.
15. The method of claim 13, wherein the ADL subscore is decreased by at least about 3 points following at least 8 weeks of administration of the compound of formula (I), or a pharmaceutically acceptable salt thereof.
16. The method of any one of claims 1-12, wherein the TETRAS performance score comprises mADL subscore, and wherein the mADL subscore is decreased by at least about 0.5 points, at least about 1 point, at least about 1.5 points, at least about 2 points, at least about 2.5 points, at least about 3 points, at least about 3.5 points, at least about 4 points, at least about 4.5 points, at least about 5 points, at least about 5.5 points, at least about 6 points, at least about 6.5 points, at least about 7 points, at least about 7.5 points, at least about 8 points, at least about 8.5 points, at least about 9 points, at least about 9.5 points or at least about 10 points following administration of the compound of formula (I), as compared to the ADL subscore of said subject prior to the administration of the compound of formula (I).
17. The method of claim 16, wherien the mADL subscore is decreased by at least about 2 points following at least 8 weeks of administration of the compound of formula (I), or a pharmaceutically acceptable salt thereof.
18. The method of claim 17, wherein the mADL subscore is decreased by at least about 3 points following at least 8 weeks of administration of the compound of formula (I), or a pharmaceutically acceptable salt thereof.
19. The method of claim 16, wherein the mADL subscore is decreased by at least about 4 points following at least 8 weeks of administration of the compound of formula (I), or a pharmaceutically acceptable salt thereof.
20. The method of any one of claims 16-19, wherein a subscore for at least one item assessed as a part of mADL subscale is decreased, wherein said item is selected from the group consisting of: item 3 (drinking from a glass); item 4 (hygene); item 5 (dressing); item 6 (pouring); item 7 (carrying); item 8 (using keys); item 9 (writing); and item 11 (overall disability).
21. The method of any one of claims 1-12, wherein the TETRAS performance score comprises mADLl 1 subscore, and wherein the mADLl 1 subscore is decreased by at least about 0.5 points, at least about 1 point, at least about 2 points, at least about 3 points, at least about 4 points, at least about 5 points, at least about 6 points, at least about 7 points, at least about 8 points, at least about 9 points or at least about 10 points following administration of the compound of formula (I), as compared to the ADL subscore of said subject prior to the administration of the compound of formula (I).
22. The method of claim 19, wherein the mADLl 1 subscore is decreased by at least about 2 points following at least 8 weeks of administration of the compound of formula (I), or a pharmaceutically acceptable salt thereof.
23. The method of claim 19, wherein the mADLl 1 subscore is decreased by at least about 2.5 points following at least 8 weeks of administration of the compound of formula (I), or a pharmaceutically acceptable salt thereof.
24. The method of any one of claims 1-23, wherein said subject does not have intention tremor.
25. The method of any one of claims 1-24, wherein said subject is a human.